Cost-effectiveness and feasibility of implementing mri-guided neoadjuvant chemotherapy to treat er-positive her2-negative breast cancers in the Netherlands

Anna Miquel-Cases, L. Steuten, Willem H. van Harten

Research output: Contribution to journalMeeting AbstractAcademic

23 Downloads (Pure)
Original languageEnglish
Article numberPCN186
Pages (from-to)A463
JournalValue in health
Volume18
Issue number7
DOIs
Publication statusPublished - Nov 2017
EventISPOR 18th Annual European Congress 2015 - MiCo - Milano Congressi, Milan, Italy
Duration: 7 Nov 201511 Nov 2015
Conference number: 18
https://www.ispor.org/event/index/2015milan

Keywords

  • Abonnement

Cite this

@article{89918dfaeb66441f956f20200fbc9d5e,
title = "Cost-effectiveness and feasibility of implementing mri-guided neoadjuvant chemotherapy to treat er-positive her2-negative breast cancers in the Netherlands",
keywords = "Abonnement",
author = "Anna Miquel-Cases and L. Steuten and {van Harten}, {Willem H.}",
year = "2017",
month = "11",
doi = "10.1016/j.jval.2015.09.1203",
language = "English",
volume = "18",
pages = "A463",
journal = "Value in health",
issn = "1098-3015",
publisher = "Elsevier",
number = "7",

}

Cost-effectiveness and feasibility of implementing mri-guided neoadjuvant chemotherapy to treat er-positive her2-negative breast cancers in the Netherlands. / Miquel-Cases, Anna; Steuten, L.; van Harten, Willem H.

In: Value in health, Vol. 18, No. 7, PCN186, 11.2017, p. A463.

Research output: Contribution to journalMeeting AbstractAcademic

TY - JOUR

T1 - Cost-effectiveness and feasibility of implementing mri-guided neoadjuvant chemotherapy to treat er-positive her2-negative breast cancers in the Netherlands

AU - Miquel-Cases, Anna

AU - Steuten, L.

AU - van Harten, Willem H.

PY - 2017/11

Y1 - 2017/11

KW - Abonnement

U2 - 10.1016/j.jval.2015.09.1203

DO - 10.1016/j.jval.2015.09.1203

M3 - Meeting Abstract

VL - 18

SP - A463

JO - Value in health

JF - Value in health

SN - 1098-3015

IS - 7

M1 - PCN186

ER -